首页> 外文期刊>Annual Review of Analytical Chemistry >Technologies for Measuring Pharmacokinetic Profiles
【24h】

Technologies for Measuring Pharmacokinetic Profiles

机译:用于测量药代动力学型材的技术

获取原文
获取原文并翻译 | 示例
           

摘要

The creation of a pharmacokinetic (PK) curve, which follows the plasma concentration of an administered drug as a function of time, is a critical aspect of the drug development process and includes such information as the drug's bioavailability, clearance, and elimination half-life. Prior to a drug of interest gaining clearance for use in human clinical trials, research is performed during the preclinical stages to establish drug safety and dosing metrics from data obtained from the PK studies. Both in vivo animal models and in vitro platforms have limitations in predicting human reaction to a drug due to differences in species and associated simplifications, respectively. As a result, in silico experiments using computer simulation have been implemented to accurately predict PK parameters in human studies. This review assesses these three approaches (in vitro, in vivo, and in silico) when establishing PK parameters and evaluates the potential for in silico studies to be the future gold standard of PK preclinical studies.
机译:遵循施用药物的血浆浓度的药代动力学(PK)曲线作为时间的函数,是药物开发过程的关键方面,包括作为药物的生物利用度,间隙和消除半衰期的这种信息。在对人类临床试验中使用的利率进行利率之前,在临床前阶段进行研究,以建立从PK研究中获得的数据的药物安全和给药度量。在体内动物模型和体外平台中,由于物种和相关简化的差异,分别具有预测对药物的人类反应的局限性。结果,已经实施了使用计算机模拟的硅实验,以准确地预测人类研究中的PK参数。该审查在建立PK参数时评估这三种方法(体外,体内,体内和硅中),并评估Silico研究的潜力,成为PK临床前研究的未来金标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号